ESR1 and breast cancer: While existing treatment options have extended survival, issues such as drug resistance and side effects persist (Giaquinto et al., 2022; Lumachi et al., 2011), creating a pressing need for the development of new anti-breast cancer drugs, particularly those targeting estrogen receptor alpha (ERα) and optimizing ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) properties (Marra et al., 2020).